Summit Therapeutics stock plunges after FDA rejects lung cancer drug

Summit Therapeutics' stock fell 19% after the FDA rejected its lung cancer drug, ivonescimab, due to insufficient overall survival benefits in a late-stage trial. The drug delayed disease progression but did not meet the primary endpoint. Summit plans to continue discussions with the FDA, citing updated data showing survival improvements.

Original reporting
Published Nov 16, 2026, 10:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$SMMT
Bearish
high confidence
Mentioned
$SMMT
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SMMTBearishHigh
01

Why it matters

The FDA's denial underscores the challenge of demonstrating overall survival benefit, a key hurdle for oncology approvals.

02

Market read

Regulatory denial drives immediate sell‑off; sector peers may experience heightened scrutiny.

03

What to watch

Potential for the company to pursue alternative regulatory pathways or partner deals to mitigate impact.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Summit Therapeutics acquired ivonescimab rights from Akeso in 2022; the drug targets PD‑1 and VEGF pathways.

Company-level read

Ticker impact

$SMMTBearishHigh confidence
Context

FDA issued a complete response letter rejecting Summit Therapeutics' lung cancer drug ivonescimab, causing a 19% pre‑market drop.

Expected impact

likely pressure as the market prices in the FDA rejection and lack of overall survival benefit.

Evidence & confidence

The FDA denial is a primary, material regulatory event for a biotech; traders typically sell on such news.

Market effects

May weigh on other oncology biotech stocks awaiting FDA decisions.

US biotech sector could see modest pullback in early trading.

Limited to markets with exposure to US biotech equities.

Counterpoint

If updated survival data later convinces the FDA, a rebound could occur, but short‑term risk remains high.

Key entities

  • Summit Therapeutics

    US‑listed biotech developing ivonescimab.

  • FDA

    U.S. Food and Drug Administration issuing the CRL.

Related articles

$SMMTHighAI 9/10

Summit Therapeutics Sinks on FDA Rejection

Summit Therapeutics (SMMT) shares fell 16.5% after the FDA rejected its lung cancer drug ivonescimab, citing insufficient evidence of overall survival benefit. The company plans to continue development, but no resubmission timeline was provided. Summit's stock closed at $11.82, its lowest since August. The FDA's decision follows positive progression-free survival results but insufficient overall survival data.

$SMMTMedAI 8/10

2 Cancer-Drug Developers Seeing Unusual Options Volume

Summit Therapeutics (SMMT) fell 15% to $12.02 after the FDA declined to approve its lung cancer drug, requesting more survival data. Citi cut its price target to $42. CG Oncology (CGON) rose 12.5% to $83.70 after its bladder cancer treatment met trial goals, reducing recurrence risk by 68%. Both saw unusual options activity, with bearish sentiment.

$SMMTHighAI 9/10

Summit Stock Falls on FDA Rejection for Lung Cancer Drug

Summit Therapeutics (SMMT) shares fell 20% after the FDA rejected its lung cancer drug, ivonescimab, due to insufficient evidence of effectiveness. The drug showed progression-free survival benefits but failed to meet overall survival endpoints. The setback delays U.S. launch plans and creates regulatory uncertainty. Year-to-date, SMMT shares are down 19.1%.

$SMMTHighAI 8/10

SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter

Summit Therapeutics (SMMT) saw price target reductions from Barclays ($18) and Citi ($42) after the FDA issued a complete response letter for its lung cancer treatment, ivonescimab. Barclays noted potential implications for the lung cancer program, while Citi cited the CRL as the reason for its reduction. Jefferies maintained a 'Buy' rating with a $30 target, stating the setback was anticipated. SMMT shares fell 11% following the news.